Evidence map›Paper›PMID 39507269›Full record

ArticleRespiratory medicine case reports2024

Persistent SARS-CoV-2 infection resolved after B-cell recovery in a patient with follicular lymphoma treated with B-cell depletion therapy.

Yuriko Sueda, Hirokazu Tokuyasu, Momoka Atsuta, Hiromitsu Sakai, Katsunori Arai, Chika Esumi, Misato Mochizuki, Tomoki Itohara, Naoki Fujisawa, Akira Yamasaki

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuriko SuedaRespiratory Medicine Division, Matsue Red Cross Hospital, Matsue City, Shimane, Japan.
Hirokazu TokuyasuRespiratory Medicine Division, Matsue Red Cross Hospital, Matsue City, Shimane, Japan.
Momoka AtsutaRespiratory Medicine Division, Matsue Red Cross Hospital, Matsue City, Shimane, Japan.
Hiromitsu SakaiRespiratory Medicine Division, Matsue Red Cross Hospital, Matsue City, Shimane, Japan.
Katsunori AraiRespiratory Medicine Division, Matsue Red Cross Hospital, Matsue City, Shimane, Japan.
Chika EsumiPathology Division, Matsue Red Cross Hospital, Matsue City, Shimane, Japan.
Misato MochizukiPharmacy Division, Matsue Red Cross Hospital, Matsue City, Shimane, Japan.
Tomoki ItoharaClinical Laboratory Division, Matsue Red Cross Hospital, Matsue City, Shimane, Japan.
Naoki FujisawaDivision of Virology, Shimane Prefectural Institute of Public Health and Environmental Science, Matsue City, Shimane, Japan.
Akira YamasakiDivision of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, School of Medicine, Faculty of Medicine, Tottori University, Yonago City, Tottori, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 68-year-old woman with follicular lymphoma was treated with chemotherapy, including the anti-CD20 monoclonal antibody obinutuzumab, and achieved remission. A month after the administration of obinutuzumab, the patient contracted coronavirus disease 2019 (COVID-19), and various antiviral drugs were administered. However, the infection had not been eliminated. One year and three months after chemotherapy, peripheral B cell recovery was achieved, and the infection had resolved. This report provides insight into the course of COVID-19 in patients with impaired humoral immunity.

Indexed as

Anti-CD20 antibodyB-cell depletion therapyFollicular lymphomaObinutuzumabPersistent SARS-CoV-2 infection

Identifiers

PMID39507269
PMCPMC11538806

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.